, Tracking Stock Market Picks
Enter Symbol:

up 60.62 %

MEDIVATION INC (MDVN) rated Buy with price target $148 by UBS

Posted on: Tuesday,  Aug 25, 2015  10:25 AM ET by UBS

UBS rated Buy MEDIVATION INC (NASDAQ: MDVN) on 08/25/2015. Previously UBS rated Buy MEDIVATION INC (NASDAQ: MDVN) on 07/17/2013., when
the stock price was $57.32. Since then, MEDIVATION INC has gained 60.62% as of 01/27/2016's recent price of $92.07.
If you would have followed the previous UBS's recommendation on MDVN, you would have gained 60.62% of your investment in 924 days.

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer?s disease, Huntington?s disease and castration-resistant prostate cancer. The Company has formed separate subsidiaries to hold the product candidates it is developing. The Company?s subsidiary Medivation Neurology, Inc. holds its Dimebon technology, and its subsidiary Medivation Prostate Therapeutics, Inc. holds its MDV300 series technology.

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/25/2015 10:25 AM Buy
86.38 148.00
as of 8/27/2015
1 Week down  -10.35 %
1 Month down  -20.67 %
3 Months down  -25.37 %
1 YTD up  44.26 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/15/2014 12:25 PM Buy
103.38 125.00
3/3/2014 1:25 PM Buy
71.77 85.00
7/17/2013 10:25 AM Buy
57.32 74.00
12/19/2012 11:25 AM Hold
54.69 59.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy